Skip to content

More naming and shaming

April 17, 2012

Biased HT* authors

A couple of years ago Athina Tatsioni and her colleagues collected 114 editorials or reviews, authored by people with financial ties to hormone therapy (HT) manufacturers, in which there appeared to be bias in favour of HT. Click here for the paper. Or get the pdf here partisan perspectives.

Tatsioni identified five prolific authors of such biased editorials, and listed the articles in an appendix. However, she did not name the offenders.  Readers had to find the appendix, count who had contributed the most, and check elsewhere for conflicts of interest.

So I’ve done that for you. Here are the experts who authored more than 10 articles each.  Unless otherwise stated, conflicts are sourced from Climacteric‘s editorial board site here.  Andrea Genazzani and Marco Gambacciani list no conflicts on that site so I’ve used other public sources here, and here. I’ve not found any public conflict of interest statements for Henry Seeger or Tomasino Simoncini.

Expert Links with the following manufacturers No of HT favourable reviews/editorials authored
Marco Gambacciani University of Pisa, Italy Bracco, Eli Lilly, General Electric, Igea, Lunar Corporation, MS&D, Novartis, Novo Nordisk, Organon, Pfizer, P&G, Schering, Solvay, Wyeth. 23
Andrea Genazzani University of Pisa, Italy Bracco, Eli Lilly, Igea, Lunar Corporation, MSD, Novartis, Novo Nordisk, Organon, Pfizer, Procter & Gamble, Schering, Solvay, and Wyeth. 39
Professor Alastair MacLennan University of Adelaide, Australia A variety of pharmaceutical companies 19
Professor Alfred O Mueck University Women’s Hospital of Tuebingen, Germany Bayer-Schering, Novartis, Novo Nordisk, Procter & Gamble, Schering-Plough/Merck Sharpe & Dohme and Solvay 32
Amos Pines consultant for distributor who represents about 20 pharma companies 21
Henry Seeger None found 15
Tomasino Simoncini None found 11
Dr David W Sturdee,Solihull Hospital, Birmingham, UK Amgen, Theramex, Procter & Gamble, Wyeth, Bayer Schering and Novo Nordisk. 31

It appears that Andrea Genazzani, Marco Gambacciani, Alfred Mueck and David Sturdee were four of the biased editorialists. Who knows if Alastair MacLennan, or Amos Pines were the fifth.

Readers of reassuring articles about the safety of postmenopausal HT by these authors, may wish to bear this in mind. See also the original Naming and Shaming here, and the special case of John Stevenson here.

Jim Thornton

*Hormone replacement therapy (HRT) changed to hormone therapy (HT) Jan 2016

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: